Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Friday, October 16, 2015

HCV Advocate Eblast: October 15, 2015
Check out what we have in store for you in the October Mid-Month Newsletter
 Hello,
You have probably noticed a lot of changes on the HCV Advocate Website in the last couple of months. We launched the newly designed and organized HCV Advocate website.  We will be fine tuning the website for the next few months as we continue to roll out all the services. We appreciate the feedback we have received and thank you for your patience.
In this month’s issue we have the follow articles:
  • Dr. David Mazoff has retired from HCSP/HCVAdvocate—read about his accomplishments and why he will be missed.
  • Disability Column Open Enrollment Final – this is a must-read for everyone who will be signing up for new insurance, Obamacare and Medicare.
  • The Five Clinical Trials: What Patients Need to Know: Are you considering volunteering for a clinical trial? If so, this will help you sift through the information to make an informed choice.
  • Snapshots: This issue features a study of the risk of hepatitis C and miscarriages and another study that comes closer to the real number of people chronically infected with hepatitis C.
  • What’s New? We are including our tattoo fact sheets from www.hepatitistattoos.org on our www.hcvadvocate.org. The tattoo fact sheets will be housed under our Fact Sheet tab.
We would also like to welcome our new Webmaster—Judy Barlow—who officially joined us in August 2015 and who has been working with David to ensure a smooth transition.
Cheers,
Alan

No comments:

Post a Comment